Sabatella G - Search Results

1

Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.

Wingerchuk DM, Fujihara K, Palace J, Berthele A, Levy M, Kim HJ, Nakashima I, Oreja-Guevara C, Wang KC, Miller L, Shang S, Sabatella G, Yountz M, Pittock SJ; PREVENT Study Group. Wingerchuk DM, et al. Among authors: sabatella g. Ann Neurol. 2021 Jun;89(6):1088-1098. doi: 10.1002/ana.26049. Epub 2021 Feb 27. Ann Neurol. 2021. PMID: 33586143 Free PMC article. Clinical Trial.

2

Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis.

Newsome SD, Kieseier BC, Arnold DL, Shang S, Liu S, Hung S, Sabatella G. Newsome SD, et al. Among authors: sabatella g. J Neurol. 2016 Sep;263(9):1778-87. doi: 10.1007/s00415-016-8182-4. Epub 2016 Jun 17. J Neurol. 2016. PMID: 27314959 Free PMC article. Clinical Trial.

3

Response to: Eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder.

Pittock SJ, Weitz I, Howard JF, Sabatella G, Mehta S, Franklin J. Pittock SJ, et al. Among authors: sabatella g. CNS Spectr. 2021 Jun;26(3):195-196. doi: 10.1017/S1092852920001625. Epub 2020 Jul 9. CNS Spectr. 2021. PMID: 32641193 No abstract available.

4

A single relapse induces worsening of disability and health-related quality of life in patients with neuromyelitis optica spectrum disorder.

Berthele A, Levy M, Wingerchuk DM, Pittock SJ, Shang S, Kielhorn A, Royston M, Sabatella G, Palace J. Berthele A, et al. Among authors: sabatella g. Front Neurol. 2023 Apr 11;14:1099376. doi: 10.3389/fneur.2023.1099376. eCollection 2023. Front Neurol. 2023. PMID: 37114235 Free PMC article.

5

Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE.

Cohan S, Kappos L, Giovannoni G, Wiendl H, Selmaj K, Havrdová EK, Rose J, Greenberg S, Phillips G, Ma W, Wang P, Lima G, Sabatella G. Cohan S, et al. Among authors: sabatella g. Mult Scler. 2018 Dec;24(14):1883-1891. doi: 10.1177/1352458517735190. Epub 2017 Oct 6. Mult Scler. 2018. PMID: 28984179 Free PMC article.

6

Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study.

Benedict RH, Cohan S, Lynch SG, Riester K, Wang P, Castro-Borrero W, Elkins J, Sabatella G. Benedict RH, et al. Among authors: sabatella g. Mult Scler. 2018 May;24(6):795-804. doi: 10.1177/1352458517707345. Epub 2017 May 9. Mult Scler. 2018. PMID: 28485186 Free PMC article. Clinical Trial.

7

Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis.

Newsome SD, Guo S, Altincatal A, Proskorovsky I, Kinter E, Phillips G, You X, Sabatella G. Newsome SD, et al. Among authors: sabatella g. Mult Scler Relat Disord. 2015 Jul;4(4):350-7. doi: 10.1016/j.msard.2015.06.004. Epub 2015 Jun 14. Mult Scler Relat Disord. 2015. PMID: 26195056 Clinical Trial.

8

Management Strategies for Flu-Like Symptoms and Injection-Site Reactions Associated with Peginterferon Beta-1a: Obtaining Recommendations Using the Delphi Technique.

Halper J, Centonze D, Newsome SD, Huang D, Robertson C, You X, Sabatella G, Evilevitch V, Leahy L. Halper J, et al. Among authors: sabatella g. Int J MS Care. 2016 Jul-Aug;18(4):211-8. doi: 10.7224/1537-2073.2015-042. Int J MS Care. 2016. PMID: 27551246 Free PMC article.

9

Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis.

Liu Y, Vollmer T, Havrdova E, Riester K, Lee A, Phillips G, Wang P, Sabatella G. Liu Y, et al. Among authors: sabatella g. Mult Scler Relat Disord. 2017 Jan;11:18-24. doi: 10.1016/j.msard.2016.11.005. Epub 2016 Nov 13. Mult Scler Relat Disord. 2017. PMID: 28104250 Free article. Clinical Trial.

10

Measuring the impact of multiple sclerosis: Enhancing the measurement performance of the Multiple Sclerosis Impact Scale (MSIS-29) using Rasch Measurement Theory (RMT).

Cleanthous S, Cano S, Kinter E, Marquis P, Petrillo J, You X, Wakeford C, Sabatella G. Cleanthous S, et al. Among authors: sabatella g. Mult Scler J Exp Transl Clin. 2017 Aug 15;3(3):2055217317725917. doi: 10.1177/2055217317725917. eCollection 2017 Jul-Sep. Mult Scler J Exp Transl Clin. 2017. PMID: 29104758 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Search Page

Filters